- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05879367
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
Study Overview
Status
Conditions
Detailed Description
This open label dose escalation and expansion study will be conducted using a standard dose-escalation design with escalating doses of eflornithine plus temozolomide at the approved dose level, followed by an expansion cohort that will further evaluate safety and preliminary efficacy of the combination at the recommended phase 2 dose.
Duration of participation will be up to 56 weeks in total per patient:
Screening Period - A maximum screening duration of 4 weeks.
Treatment Period - Up to 48 weeks.
Follow-Up Visit - 4 weeks from last treatment.
A total of up to 66 patients will be enrolled in a non-randomized fashion (patients may be added to any of the dose levels below the RP2D to a maximum of approximately 20 per dose level with the intent of further characterizing safety and pharmacokinetics).
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Monika Varga
- Phone Number: 6506569424
- Email: monika.varga@orbustherapeutics.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama at Birmingham
-
Principal Investigator:
- Louis B Nabors, MD
-
Contact:
- Thiru Pillay
- Phone Number: 205-934-1432
- Email: Tpillay@uabmc.edu
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Hospital
-
Principal Investigator:
- Tobias Walbert, MD, PhD, MPH
-
Contact:
- Meghan Gauronskas
- Phone Number: 313-725-7871
- Email: mgauron1@hfhs.org
-
Contact:
- Angela Dunn
- Phone Number: 313-725-7870
- Email: adunn6@hfhs.org
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center - Herbert Irving Pavilion
-
Contact:
- Alicia Bargo
- Phone Number: 212-342-4435
- Email: ab5172@cumc.columbia.edu
-
Contact:
- Maria Diaz, MD
- Phone Number: 212-342-0571
- Email: md4157@cumc.columbia.edu
-
Principal Investigator:
- Maria Diaz, MD
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University
-
Principal Investigator:
- Annick Desjardins, MD, FRCPC
-
Contact:
- Erin Severance
- Phone Number: 919-668-6230
- Email: erin.k.bell@duke.edu
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- The Cleveland Clinic
-
Principal Investigator:
- David Peereboom, MD
-
Contact:
- David Peereboom, MD
- Phone Number: 216-445-6068
- Email: peerebd@ccf.org
-
Contact:
- Rachel Hufsey, RN
- Email: hufseyr@ccf.org
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Recruiting
- Lifespan Cancer Institute/Rhode Island Hospital
-
Principal Investigator:
- Eric Wong, MD
-
Contact:
- Nuno Rodrigues, RN
- Phone Number: 401-444-3059
- Email: 908306@Lifespan.org
-
Contact:
- Francesca Rothell, MS
- Phone Number: 401.606.5488
- Email: frothell@Lifespan.org
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- UT MD Anderson Cancer Center
-
Contact:
- Carlos Kamiya Matsuoka, MD
- Phone Number: 713-408-3538
- Email: CKamiya@mdanderson.org
-
Contact:
- Evguenia Gachimova, RN
- Phone Number: 832-266-3519
- Email: EGachimova@mdanderson.org
-
Principal Investigator:
- Carlos Kamiya Matsuoka, MD
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- University of Utah, Huntsman Cancer Institute
-
Principal Investigator:
- Howard Colman, MD, PhD
-
Contact:
- Rachel Kingsford
- Phone Number: 801-585-0115
- Email: rachel.kingsford@hci.utah.edu
-
Contact:
- Yuri Kida
- Phone Number: 801-646-4397
- Email: yuri.kida@hci.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype per WHO 2021 tumor classification.
- Completed external beam radiation therapy per standard of care.
- Must have received at least 80% of planned daily doses of TMZ during chemoradiation.
- Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.
- Willing to abstain from intercourse or use acceptable contraceptive methods.
- If taking corticosteroids, must be on a stable or decreasing dose.
Exclusion Criteria:
- Recent history of recurrent or metastatic cancer that could confound response assessments
- Prior systemic chemotherapy for GBM other than temozolomide during external beam radiation therapy.
- Prior Optune treatment.
- Active infection or serious intercurrent medical illness.
- Poorly controlled seizures.
- Significant cardiac disease within 6 months of enrollment.
- Poorly controlled diabetes.
- Use of another investigational agent within 30 days of enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eflornithine Dose Level 1 + Temozolomide
|
Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Other Names:
Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
Other Names:
|
Experimental: Eflornithine Dose Level 2 + Temozolomide
|
Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
Other Names:
Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Other Names:
|
Experimental: Eflornithine Dose Level -1 + Temozolomide
|
Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
Other Names:
Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vital Signs (Heart and Respiratory Rate)
Time Frame: 52 weeks
|
Change from Baseline in Heart Rate and Respiratory Rate
|
52 weeks
|
Vital Signs (Blood Pressure)
Time Frame: 52 weeks
|
Change from Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
|
52 weeks
|
Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests
Time Frame: 52 weeks
|
Lab abnormalities by CTCAE v5.0 Grade
|
52 weeks
|
Assessment of Dose Limiting Toxicities
Time Frame: 8 weeks
|
Protocol Defined Dose Limiting Toxicities
|
8 weeks
|
Incidence of TEAEs All Grades
Time Frame: 52 weeks
|
All Grades
|
52 weeks
|
Incidence of TEAEs Grade 3+
Time Frame: 52 weeks
|
Grade 3+
|
52 weeks
|
Incidence of TEAEs Serious
Time Frame: 52 weeks
|
Serious
|
52 weeks
|
Incidence of TEAEs Leading to Discontinuation
Time Frame: 48 weeks
|
Leading to Discontinuation
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 52 weeks
|
Per RANO Criteria as assessed by MRI
|
52 weeks
|
Overall Response Rate
Time Frame: 52 weeks
|
Per RANO Criteria as assessed by MRI
|
52 weeks
|
Pharmacokinetics Cmax
Time Frame: Baseline to Steady State (2 weeks)
|
observed maximum concentration
|
Baseline to Steady State (2 weeks)
|
Pharmacokinetics Cmin
Time Frame: Baseline to Steady State (2 weeks)
|
observed minimum concentration
|
Baseline to Steady State (2 weeks)
|
Pharmacokinetics Tmax
Time Frame: Baseline to Steady State (2 weeks)
|
time of observed maximum concentration
|
Baseline to Steady State (2 weeks)
|
Pharmacokinetics AUCt
Time Frame: Baseline to Steady State (2 weeks)
|
area under the concentration-time curve
|
Baseline to Steady State (2 weeks)
|
Pharmacokinetics lambdaz
Time Frame: Baseline to Steady State (2 weeks)
|
elimination rate constant
|
Baseline to Steady State (2 weeks)
|
Pharmacokinetics t 1/2
Time Frame: Baseline to Steady State (2 weeks)
|
elimination half life
|
Baseline to Steady State (2 weeks)
|
QTcF-Concentration Relationship
Time Frame: Baseline to Steady State (2 weeks)
|
Assessment of change in QTcF relative to plasma concentration of eflornithine
|
Baseline to Steady State (2 weeks)
|
Assessment of QTcF
Time Frame: Baseline to Steady State (2 weeks)
|
Change from baseline in QTcF
|
Baseline to Steady State (2 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Howard Colman, MD, PhD, Huntsman Cancer Institute/ University of Utah
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Trypanocidal Agents
- Ornithine Decarboxylase Inhibitors
- Temozolomide
- Eflornithine
Other Study ID Numbers
- OT-21-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Eflornithine (Dose Level 1)
-
Ehab L AtallahRecruitingAcute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic LeukemiaUnited States
-
Anagram Therapeutics, Inc.RecruitingExocrine Pancreatic InsufficiencyUnited States
-
University of ChicagoRecruitingLymphoma | Hodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedLeukemia | Leukemia, B-Cell, ChronicUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisLinKinVaxRecruitingHead and Neck Carcinoma | Adult DiseaseFrance
-
Nebraska Methodist Health SystemActive, not recruitingOropharynx Cancer | HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical StageUnited States
-
Adlai Nortye Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Advanced LymphomaUnited States, China
-
ThromboGenicsCompletedDiabetes Mellitus | Diabetic Retinopathy | Diabetic Macular EdemaUnited States
-
ThromboGenicsCompletedDiabetes Mellitus | Diabetic Retinopathy | Diabetic Macular EdemaUnited States